tbuckley/cabot-search huggingface dataset:
EFFECTIVENESS OF ECCENTRIC HIP ABDUCTION EXERCISE ON KNEE ABDUCTION MOMENT FOR ONE-YEAR FOLLOW-UP
Authors: Yasuaki Okawa, Yasuaki Saho, Kana Iwano, Sayaka Yasui
Journal: British Journal of Sports Medicine (2017)

Background An ACL tear is one of the most serious injuries in sports, especially for females. A clinically based ACL injury prediction algorithm is thought to identify female athletes with high Knee Abduction Moment and has gained popularity. The hip abductors are considered as one of most important muscle groups to control knee position. Objective To investigate the effectiveness of eccentric hip abduction exercise on Knee Abduction Moment. Design Intervention, one-year follow-up. Setting University Division 1 (cheerleading), Clinical setting Participants 18 knees of 9 female freshman (18 yrs old). Intervention We used an eccentric hip abduction exercise. To start the athletes lay on contralateral side, lifting the upper leg to the end of hip abduction range of motion. Then, the partner pushed the leg downwards until the foot hit the other foot laying ob the ground while the athlete resisted. The athletes implemented one set of 10 repetitions each training session as part of the warm-up routine. Main Outcome Measurements The probability of High Knee Load was calculated by scoring points of tibia length, knee valgus motion, knee flexion ROM, body mass, and quadriceps:hamstrings torque ratio. Knee Abduction Moment was measured at baseline and one year after starting training. We defined a 75% or higher probability of high knee load as being at a high risk. Results At baseline, when the 9 athletes entered university as freshmen, there 3 out of 18 knees were scored as being at high risk, compared to 1 knee one year after implementing the eccentric knee abduction exercise. Conclusions Implementing an eccentric hip abduction exercise as part of routine warm-up has the potential to decrease the number of knees with high knee load among collegiate cheerleaders.
RACIAL DISPARITIES AND TEMPORAL TRENDS IN DEMOGRAPHICS AND CLINICAL CHARACTERISTICS OF PATIENTS SCREENED FOR TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Ron Waksman, Kyle Buchanan, M. Chadi Alraies, Toby Rogers, Arie Steinvil, Edward Koifman, Joelle Salmon, Jiaxiang Gai, Rebecca Torguson, Petros Okubagzi, Itsik Ben-Dor, Augusto Pichard, Lowell Satler
Journal: Journal of the American College of Cardiology (2017)
Differences in pain, symptom burden, and opioid use among cancer pain patients with active versus non-active disease.
Authors: Karina J Bouffard, Lakshmi Koyyalagunta, Salahardin Abdi, Mike Hernandez, Diane M. Novy
Journal: Journal of Clinical Oncology (2013)

e20568 Background: Many cancer survivors with non-active disease suffer with pain and other symptoms. This study investigated differences in symptoms and opioid use among cancer pain patients with active versus non-active disease. Methods: Data were obtained from 518 consecutive new patients seen at the Pain Management Center of MD Anderson Cancer Center from 01/01/09 to 06/30/09. Measures: Usual pain was rated on the Brief Pain Inventory. The Edmonton Symptom Assessment Scale (ESAS) was used for ratings of fatigue, shortness of breath, poor appetite, depression, anxiety, drowsiness, difficulty thinking clearly and insomnia. Opioid use was calculated in morphine equivalency daily dose (MEDD) milligrams based on the sum of long- and short-acting opioids used per day. Analyses of Data: Independent samples t-tests were used to make comparisons between patients with active versus non-active disease on continuous variables. Chi-square tests were used to make comparisons across disease status on categorical variables. Results: 349 patients had active disease; 169 patients had non-active disease. Patients with active disease received significantly higher MEDD (125.6 ± 158.8 mg) versus patients with non-active disease (74.4 ± 87.0 mg). Patients with active disease reported significantly higher mean scores on fatigue, poor appetite, and drowsiness. Average weekly pain scores were comparable and moderately high for both groups of patients. Other symptoms and clinical characteristics were not significantly different across disease status. Conclusions: Plausible explanations for the higher opioid use and symptom burden among patients with active disease are cancer treatments and disease progression. A higher level of pain medication is often needed to achieve pain management during active treatment or following recent surgery. The finding of higher fatigue, poor appetite, and drowsiness among those with active disease is also consistent with the symptom burden expected from treatment. Although patients with active disease have a greater symptom burden and need for pain medication, there is a need for pain and symptom management among patients in the non-active disease phase of survivorship.
Health Progress 1936 to 1945: A Supplement to Twenty-Five Years of Health Progress
Journal: JAMA (1949)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
EFFECT OF BODY MASS INDEX ON MORTALITY AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: J-SHAPED CURVE
Authors: Rocío González Ferreiro, Diego Lopez Otero, Antonio J. Muñoz-García, Pablo Avanzas, Isaac Pascual, Juan H. Alonso Briales, Ramiro Trillo Nouche, Federico Pun Chinchay, Manuel Jimenez Navarro, Jose Maria Hernandez Garcia, Cesar Moris, Jose Ramon Gonzalez Juanatey
Journal: Journal of the American College of Cardiology (2017)
OBSTRUCTIVE SLEEP APNEA AND DIABETES MELLITUS HAVE SYNERGISTIC EFFECTS ON ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
Authors: Chieh Yang Koo, Luciano Drager, Hee-Hwa Ho, Thet Hein, Man-Hong Jim, Mark Chan, Mark Richards, Huay-Cheem Tan, Bee-Choo Tai, Junjie Zhang, Rishi Sethi, Chi-Hang Lee
Journal: Journal of the American College of Cardiology (2017)
Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure
Authors: Maria D’Apolito, Xueliang Du, Haihong Zong, Alessandra Catucci, Luigi Maiuri, Tiziana Trivisano, Massimo Pettoello-Mantovani, Angelo Campanozzi, Valeria Raia, Jeffrey E. Pessin, Michael Brownlee, Ida Giardino
Journal: Journal of Clinical Investigation (2010)
Use of Gemcitabine, Cisplatin and Methylprednisolone (GEM-P) with or without Rituximab in Relapsed and Refractory Patients with Diffuse Large B Cell Lymphoma (DLBCL).
Authors: Bhawna Sirohi, David Cunningham, Andy Norman, Michele Trumper, Sheela Rao, Tracey Murray, Yvonne Prior, Geoffrey Chong, Kim Last, Andrew Wotherspoon
Journal: Blood (2005)
A multicentre phase 2 study of carboplatin (C) plus pegylated liposomal doxorubicin (PLD) as first-line chemotherapy for patients (pts) with advanced or recurrent endometrial carcinoma (AEC): The END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer) Group
Authors: D. Lorusso, S. Pignata, G. Scambia, V. Zagonel, N. Riva, A. Febbraro, C. Pisano, S. Greggi, E. Breda, A. Morabito
Journal: Journal of Clinical Oncology (2006)

5041 Background: Anthracyclines and platinum derivates are active drugs for pts with AEC, but new schedules with higher efficacy and better tolerability are needed. A prospective phase 2 study was conducted to describe tolerability and activity of C + PLD in pts with AEC. Methods: Pts with chemo-naïve AEC, PS ≤2, aged less than 75 years and with at least one measurable lesion were eligible. Treatment was C (AUC 5) + PLD (40 mg/m 2 ) on day 1 every 4 weeks, up to 6 cycles. A single-stage design was applied. With objective response as primary endpoint, type I error = 0.05 and II error = 0.10, p 0 = 0.20, p 1 = 0.40, 42 patients were needed, with at least 13 objective responses to define the treatment active. Response was assessed by RECIST and toxicity was coded with NCI-CTC. Results: From November 2002 to July 2005, 42 pts were enrolled at 5 Institutions. Median age was 64 years (31–74). PS was 0/1/2 in 28/13/1 pts, respectively. 62% of pts were stage IV. Out of 40 pts out of treatment, 3 complete (7.5%) and 20 partial responses (50%) have been already observed, for an overall response rate of 57.5% (95% exact CI: 40.9–73.0). One death potentially related to treatment was recorded (death at home for unknown reasons after 6 th cycle). Other relevant toxicities (% of pts) were g3/4 neutropenia 30%/15%, febrile neutropenia 5%, g3/4 thrombocytopenia pts 17.5%/5%, g3/4 anemia 32.5%/5%, g3 heart rhythm 1 pt, g2 liver toxicity 1pt. Skin toxicity was mild: g1 12.5%, g2 7.5%, g3 5%. Hair loss: complete 1 pt, partial 12.5%. Conclusions: The combination of C and PLD shows a good activity and a favourable toxicity profile in first-line chemotherapy of pts with AEC, deserving further studies in this setting. No significant financial relationships to disclose.
An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma
Authors: Tarec Christoffer El-Galaly, Chan Yoon Cheah, Mette Dahl Bendtsen, Gita Thanarasjasingam, Roopesh Kansara, Kerry J Savage, Joseph M. Connors, Neta Goldschmidt, Adir Shaulov, Umar Farooq, Laurie H Sehn, Eldad J Dann, Carrie A Thompson, Tsofia Inbar, Brian K Link, Matthew J Maurer, Inger Lise Gade, Maja Bech Juul, Jakob W Hansen, Staffan Holmberg, Thomas S Larsen, Stephen Opat, N George Mikhaeel, John F Seymour, Michael Roost Clausen, Daniel Smith, Michael Gilbertson, Grzegorz S Nowakowski, Sabrina Cordua, Martin Hutchings, Diego Villa
Journal: Blood (2016)
THE ADDITION OF RENAL IMPAIRMENT TO THE CHA2DS2-VASC SCORE AS A PREDICTOR OF THROMBOEMBOLISM AND MORTALITY IN PATIENTS WITHOUT ATRIAL FIBRILLATION
Authors: Christine Parsons, Stephen Cha, Win-Kuang Shen, Santosh Desai, Salma Patel, Alanna Chamberlain, Sushil Allen Luis, Maria Aguilar, Bart Demaerschalk, Farouk Mookadam, Fadi Shamoun
Journal: Journal of the American College of Cardiology (2017)
Activity of crizotinib in relapsed MET amplified malignancies: Results of the French AcSé Program.
Authors: Gilles Vassal, Marie-cecile Ledeley, Christophe Tournigand, Thomas Aparicio, Isabelle Ray-Coquard, Luc Taillandier, Bernard Escudier, Benoit You, Anthony Goncalves, Catherine Lombard Bohas, Jean Francois Seitz, Thierry Andre, Jean-Philippe Merlio, Laurent Arnould, Gilbert Ferretti, Yves Menu, Thomas Mortier, Etienne Lonchamp, Celine Mahier - Ait Oukhatar, Denis Moro-Sibilot
Journal: Journal of Clinical Oncology (2015)

2595 Background: Crizotinib (crz) is registered only for the treatment of patients (pts) with ALK-translocated lung cancer. Crz is also a MET inhibitor. MET is amplified in several malignancies. Activity of crz in MET amplified (+) tumors was explored as part of the French National Cancer Institute (INCa) AcSé program, including both access to tumor molecular diagnosis and an exploratory multi-tumor 2-stage design phase II trial. We report here results in pts with MET + tumors. Methods: MET analysis on formalin-fixed, paraffin-embedded tumor samples was proposed in 170 investigating centers and performed in 28 regional INCa molecular genetic centers. MET+ was explored by FISH in tumor samples showing an IHC score of ≥2+. Pts with a tumor showing > 6 MET copies, whatever the MET/CEN7 ratio, were eligible, providing they were not eligible for any other academic or industry trial evaluating another MET inhibitor. Study treatment consisted in crz 250 mg BID. The objective response rate (ORR) and disease control rate (DCR) were assessed every 8 weeks, using RECIST v1.1. Results: From Aug. 2013 to Dec. 2014, MET was prospectively analyzed in the tumors of 3,044 pts, and amplification (median copy number=7) was found in 100/1,358 lung, 19/591 colon, 5/275 ovary, 13/218 glioblastoma, 10/180 gastric, 1/63 hepatocarcinoma, 1/50 kidney and 0/11 thyroid. 46 pts were enrolled in the trial. Median age: 59 yrs (range 30–92), 65% males and 95% metastatic disease at study entry. 23 pts were still on treatment at the cut-off date, 23 have stopped crz (18 PD, 2 adverse events, 1 death, 2 others reasons). Among the 30 pts evaluable for response at 8 weeks, we observed 4 PR and 8 SD, leading to DCR=40% [95% CI: 23-59]. At 6 months, DCR=15% achieved in 4/26 evaluable pts (3 lung, 1 gastric). Crz was well tolerated with only 8 grade ≥3 adverse events (AEs) or SAE. Most common AEs, mainly grade 1, were fatigue (64 % pts), anemia (53%), ALAT and ASAT increased (both 53%) and visual disorders (50%). Conclusions: Nationwide biomarker-driven access to crz for pts with MET+ malignancy is feasible. Crz showed responses in MET+ lung. No response was observed in MET+ colon cancer. Clinical trial information: NCT02034981. Lung N=14 Colon N=10 Gastric N=2 Ovary N=2 Cholangiocarcinoma N=1 Other (urachus) N=1 PR 4 SD 4 2 1 1 PD 6 8 1 2 1
Development of a needle biopsy-based genomic test to improve discrimination of clinically aggressive from indolent prostate cancer.
Authors: Eric A. Klein, Tara Maddala, Carl Millward, Diana B. Cherbavaz, Sara Moscovita Falzarano, Dejan Knezevic, William F. Novotny, Mark Lee, Cristina Magi-Galluzzi
Journal: Journal of Clinical Oncology (2012)

4560 Background: Standardized, quantitative tools are needed to improve discrimination of clinically aggressive from indolent prostate cancer at diagnosis. We previously identified multiple genes and biological pathways in radical prostatectomy (RP) specimens associated with clinical recurrence and adverse pathology. We evaluated whether measurement of these genes in prostate needle biopsy (Bx) specimens predicts adverse pathology - high grade (GS ≥ 4+3) and/or non-organ-confined disease (pT3) - in a separate study of AUA low-intermed risk pts treated w/ RP. Methods: All AUA low-intermed risk (cT1-T2a, GS 3+3/3+4) pts treated w/ RP &lt;6 mos from Bx at Cleveland Clinic (1999-2007) w/ available Bx tissue and &lt;3 pos cores were evaluated. Expression of 81 prognostic genes identified in previous RP studies and 5 reference genes was quantitated by RT-PCR in 60 µm manually microdissected FPE prostate needle Bx tissue. Association of gene expression w/ adverse pathology was analyzed by logistic regression controlling false discovery rate (FDR) using Storey’s method. Results: RT-PCR was successful for 167 of 171 (98%) pts (92 AUA low, 75 intermed). At RP, 58 pts (35%) had high-grade and/or non-organ confined disease. 58 of 81(72%) genes predicted high grade and/or non-organ-confined disease (FDR&lt;10%), including all stromal response and androgen genes and the majority of cellular organization genes (82%). Proportionately fewer proliferation (40%), stress response (29%), and basal epithelial (25%) genes were associated w/ adverse path. Androgen and cellular organization genes consistently predicted lower risk; stromal response and proliferation genes predicted higher risk; (majority of std odds ratios &gt;1.5, comparable to the prognostic strength of ER in breast cancer). Conclusions: Genes and biological pathways associated w/ clinically aggressive prostate cancer in RP specimens can be reliably measured by RT-PCR from fixed prostate needle biopsies and predict high-grade, non-organ-confined disease. These results support the potential value of a Bx-based assay to inform selection of immediate treatment or active surveillance for pts diagnosed with prostate cancer on needle Bx.
PREVALENCE AND EVOLUTION OF SLEEP DISORDERED BREATHING IN ACUTE MYOCARDIAL INFARCTION
Authors: Jeanette Ting, Li-Ling Tan, Iswaree Balakrishnan, Aruni Seneviratna, Mark Chan, Mark Richards, Bee-Choo Tai, Lieng Ling, Chi-Hang Lee
Journal: Journal of the American College of Cardiology (2017)
NEOD001 DEMONSTRATES CARDIAC BIOMARKER RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS: RESULTS FROM THE PHASE 1/2 STUDY
Authors: Michaela Liedtke, Raymond Comenzo, Heather Landau, Vaishali Sanchorawala, Brendan Weiss, Jeffrey Zonder, Jackie Walling, Gene Kinney, Martin Koller, Dale B. Schenk, Spencer Guthrie, Enchi Liu, Morie Gertz
Journal: Journal of the American College of Cardiology (2017)
Blockage of IL-6 Mediated JAK2/STAT3 Cell Signaling Pathway by sIL-6R Effectively Inhibited the Growth of Multiple Myeloma Cell.
Authors: Ju-won Park, Kwang-Sung Ahn, Young-Ju Kim, Eunkyung Bae, Yong-Yeol Lee, Sung-Soo Yoon, Inho Kim, Seonyang Park, Byoung-Kook Kim
Journal: Blood (2006)
Whole-Genome Sequencing of Primary Central Nervous System Lymphoma and Diffuse Large B-Cell Lymphoma
Authors: Kenichi Yoshida, Yuichi Shiraishi, Kenichi Chiba, Yusuke Okuno, Rie Nakamoto-Matsubara, Shunichi Koriyama, Tetsuichi Yoshizato, Yusuke Shiozawa, Keisuke Kataoka, Hiroo Ueno, June Takeda, Hiroko Tanaka, Azusa Hayano, Jumpei Homma, Junya Fukai, Koji Kajiwara, Makoto Ideguchi, Yoshihiro Komohara, Naoki Yajima, Naoto Tsuchiya, Masakazu Sano, Masayuki Nitta, Yoshihiro Muragaki, Mamiko Sakata-Yanagimoto, Yasuo Iwadate, Hiroaki Hondoh, Satoru Miyano, Shigeru Chiba, Ryuya Yamanaka, Seishi Ogawa
Journal: Blood (2016)
REGIONAL VARIATIONS IN IN-HOSPITAL OUTCOMES AND HEALTHCARE RESOURCE UTILIZATION IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT IN THE UNITED STATES
Authors: Tanush Gupta, Dhaval Kolte, Sahil Khera, Kashish Goel, Pedro Villablanca, Wilbert Aronow, Howard Cooper, Charanjit Rihal, Anna Bortnick, David Slovut, Cynthia Taub, Mark Menegus, Robert Pyo, Gregg Fonarow, Julio Panza, Mario Garcia, Deepak Bhatt
Journal: Journal of the American College of Cardiology (2017)
Incidence of Procedure-Related Major Adverse Cardiac EventsFollowing Alcohol Septal Ablation for Symptomatic HypertrophicObstructive Cardiomyopathy: A European Multicenter Study
Authors: Josef Veselka, Thorsten Lawrenz, Christoph Stellbrink, David Zemánek, Marian Branny, Jaroslav Januška, Ladislav Groch, Pawel Dimitrow, Jan Krejčí, Maciej Dabrowski, Stanislav Mizera, Horst Kuhn
Journal: Journal of the American College of Cardiology (2012)
Sustained Overall Survival Benefit with Lenalidomide Plus Dexamethasone Versus No Treatment in Patients with Smoldering Myeloma at High Risk of Progression to Myeloma: Long Term Analysis
Authors: Maria-Victoria Mateos, Miguel-T Hernandez, Pilar Giraldo, Javier De La Rubia, Felipe De Arriba, Lucia Lopez-Corral, Laura Rosiñol, Bruno Paiva, Luis Palomera, Joan Bargay, Albert Oriol, Felipe Prosper, Javier Lopez, Jose-María Arguiñano, Nuria Quintana, Jose Luis Garcia, Joan Bladé, Juan José Lahuerta, Jesus San Miguel
Journal: Blood (2016)
Phase I dose-escalation trial investigating the safety and tolerability of EPO906 plus gemcitabine in patients with advanced cancer
Authors: J. J. Rinehart, J. D. Rothermel, J. Anderson, P. Lorusso
Journal: Journal of Clinical Oncology (2004)

3100 Background: EPO906, a novel epothilone, is a microtubule stabilizer that has demonstrated clinical cytotoxic activity in taxane-sensitive, -resistant, and -refractory tumors and, unlike taxanes, is not associated with myelosuppression, alopecia, or infusion-related hypersensitivity. EPO906 and gemcitabine, an inhibitor of DNA synthesis, have different mechanisms of action and non-overlapping toxicity profiles and may have synergistic antitumor activity. In a phase I, multicenter trial, we evaluated the safety and tolerability of EPO906 in combination with gemcitabine for the treatment of advanced cancers. Methods: Eligible patients (pts) had stage IV disease with ≥ 1 measurable lesion and performance status grade ≤ 2. Pts received weekly EPO906 via 5-min IV infusion starting at 0.5 mg/m2, immediately followed by gemcitabine 800 mg/m2 via 30-min IV infusion, for 3 wks followed by 1 wk rest. EPO906 was escalated in subsequent cohorts by 0.5-mg/m2 increments to 2.5 mg/m2 (the probable MTD of EPO906 alone for the 3 wk on/1 wk off schedule). Results: In total, 24 pts were enrolled in 5 cohorts treated with 0.5 mg/m2 (n = 4), 1.0 mg/m2 (n = 4), 1.5 mg/m2 (n = 4), 2.0 mg/m2 (n = 6) and 2.5 mg/m2 (n = 6). Median age was 54 yrs (range, 27–75 yrs). No DLTs were reported in pts treated with EPO906 at doses up to 2.0 mg/m2. In the 2.5-mg/m2 cohort, 4 of 6 pts experienced DLTs, including grade (gr) 3 diarrhea (n = 3), nausea (n = 1), and dizziness (n = 1). Thus, the MTD of EPO906 in combination with gemcitabine is 2.0 mg/m2. Most common nonhematologic toxicities (any gr) included diarrhea (n = 15), nausea (n = 15), and fatigue (n = 12). Hematologic toxicities included gr 4 neutropenia (n = 1) and gr 3 anemia (n = 4), neutropenia (n = 3), leukopenia (n = 2), and thrombocytopenia (n = 1). After 2 cycles of therapy, RECIST tumor assessment in 16 evaluable pts showed 1 pt with a partial response and 7 with stable disease. Conclusion: These preliminary data indicate that the combination of EPO906 and gemcitabine is generally safe and well tolerated. Future studies will fully characterize the role of EPO906 in combination with gemcitabine in the treatment of advanced cancers. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Pharmaceuticals Corp. Berlex; Novartis Pharmaceuticals Corp. Novartis Pharmaceuticals Corp. August A. Fink Memorial Foundation Novartis
DAPAGLIFLOZIN ATTENUATES DIABETIC CARDIOMYOPATHY AND THE ACTIVATION OF THE NLRP3/ASC INFLAMMASOME IN MICE WITH TYPE-2 DIABETES: A GLUCOSE-LOWERING AND SGLT-2 INDEPENDENT EFFECT
Authors: Yumei Ye, Mandeep Bajaj, Yochai Birnbaum
Journal: Journal of the American College of Cardiology (2017)